We compared health-related quality-of-life (HRQL) after intensity-modulated radiotherapy (IMRT) with statuses obtained after old and new protocols of three-dimensional conformal radiation therapy (3DCRT) for localized prostate cancer. We measured the general and disease specific HRQL using the MOS 36-Item Health Survey (SF-36), and the University of California, Los Angeles Prostate Cancer Index (UCLA PCI), respectively. IMRT resulted in similar profiles of general and disease-specific HRQL to two other methods within the first year after treatment. Moreover, IMRT gave rise to comparable urinary, intestinal and sexual side effects despite the high dose of radiation applied.
Introduction
In recent years, advances in the screening of prostate cancer have allowed detection of the disease at an earlier stage. As locally confined prostate carcinomas rarely exhibit rapid progression, it is likely that patients with localized prostate cancer will live for a long time. Thus, health-related quality-of-life (HRQL) may play a crucial role in determining of treatment modality.
While there are various treatment options for nonmetastatic prostate cancer, external-beam radiation therapy (EBRT) with neoadjuvant hormone therapy has become one of the standard modalities, especially for locally advanced cancer. 1 It is well known that irradiation can induce bladder irritability, rectal irritability, and erectile dysfunction. 2 On the other hand, while the probability of eradicating prostate cancer increases with increasing dose, 3, 4 conventional radiotherapy like fourfield irradiation has failed to be tolerable at doses exceeding 70 Gy due to high rates of severe rectal and bladder toxicities. 5 The recently developed intensitymodulated radiation therapy (IMRT) has been shown to improve local control and disease-free survival in patients with localized prostate cancer. 6 Zelefsky et al. 7 reported that IMRT significantly reduced acute and rectal toxicities compared to conventional radiotherapy techniques despite a significant dose escalation. However, there have been few studies that measured HRQL after IMRT using internationally validated outcome methods. This study compares HRQL between IMRT and 3-dimensional conformal radiation therapy (3DCRT) in Japanese men.
Materials and methods

Patient population
Between January 2000 and December 2004, 46 patients underwent the old protocol of 3DCRT, 38 new protocols of 3DCRT and 61 IMRT for their clinically localized prostate cancers at our institution. Basically, we performed radiotherapy combined with neoadjuvant endocrine therapy for all patients; just two did not receive neoadjuvant hormone therapy. One patient underwent antiandrogen monotherapy, 19 LHRH analog monotherapy, and 123 maximal androgen blockade therapy (LHRH analog plus antiandrogen) before radiation therapy. The average period of neoadjuvant hormone therapy was 4.8 months (3-48).
We previously described three concrete methods of irradiation. 8 In brief, for the old 3DCRT protocol, 46 Gy in 23 fractions were given by the four-field box technique, with multileaf collimator (MLC) confirmation to the clinical target volume (CTV), followed by an additional 24 Gy in 12 fractions, with the dynamic-arc conformal technique. CTV included the prostate or the prostate plus seminal vesicle, while leaf margins of 7 or 15 mm were directly applied to the CTV according to the local stage. For the new 3DCRT protocol, two lateral dynamic arcs with 1001 rotation were used by dynamic conformal fitting of MLCs to the planning target volume (PTV), in which 3 mm margins were generally placed from the edge of the PTV to the tips of the MLCs. CTV included the prostate, the prostate plus the proximal two-thirds of the seminal vesicle or the prostate plus the whole seminal vesicle, according to local stage. The PTV was made up from the CTV by applying a 0.9 mm margin elsewhere, except for the posterior border where a 6 mm margin was added. For the IMRT protocol, a five-field dynamic multileaf collimator technique was used. Inverse treatment planning by computer optimization was used with the Helios system (Varian Medical System). The settings for the CTV and PTV were the same as those for the new 3DCRT protocol. In the new 3DCRT and the IMRT protocols, the dose-volume constraints for the PTV, rectal wall, bladder wall and the bowels were set based on an analysis of the dose-volume histogram (DVH). However, no constraints for the DVHs were applied in the old 3DCRT protocol. 8 The dose constraints for the rectal wall were as follows; no more than 1% of the rectal wall volume should receive more than the prescription dose, no more than 25% of the rectal wall volume should receive more than 70 Gy, no more than 35% of the rectal wall volume should receive more than 60 Gy and no more than 60% of the rectal wall volume should receive more than 40 Gy. These goals were generally very close to the averaged values at each dose level in the old 3DCRT protocol except for high dose points. This means that the rectal toxicities were expected to be similar to or slightly worse than those in the old 3DCRT. With respect to the bladder wall, no more than 60% of the bladder wall volume should receive more than 40 Gy and no more than 35% of the bladder wall volume should receive more than 70 Gy. Therefore, the bladder dose is higher in the IMRT protocol than the old 3DCRT protocol.
Between 2000 and March 2003, the old 3DCRT protocol was basically applied. Between May 2003 and 2004, radiation methods (new 3DCRT and IMRT) and planned doses were selected based on the clinical stage of prostate cancer, and on patient medical history. Namely, a higher-staged local disease was subjective to IMRT, and patients with poorly controlled diabetes mellitus and/or on anticoagulant medications were planned to receive a lower dose of radiation. All patients were informed of their cancer diagnosis before being asked to fill out the HRQL questionnaires. Every patient who agreed to participate in this study received a questionnaire from his urologist.
HRQL methodology
We measured general and prostate-specific HRQL using 2 types of instruments. General HRQL was assessed using the Medical Outcomes Study 36-Item Short Form (SF-36) 9 based on a general scales covering five physical and four emotional domains. These eight domains were scored separately from 0 to 100. A higher score represented a better quality-of-life. Prostate-specific HRQL was assessed using the University of California, Los Angeles Prostate Cancer Index (UCLA PCI), which is a 20-item questionnaire that quantifies prostate cancerspecific HRQL in six separate domains including urinary function, urinary bother, bowel function, bowel bother, sexual function and sexual bother. 10 These six domains were scored separately from 0 to 100, a higher score representing a better outcomes. Both questionnaires have already been translated into Japanese and their validity and reliability have been previously tested.
11,12 HRQL was assessed before initiation of radiation therapy, just after its termination, and 1 year after its termination. Basically this study was conducted transversely, but, for many patients, the questionnaires were answered at different timings.
Statistical analysis
Quality-of-life scores for the various domains are shown as mean values according to scales of 0 to 100, with a higher score always representing a better HRQL. Statistical analysis was performed using the chi-square authorization, a two-tailed Student's t-test, and a Mann-Whitney U test. A P-value o0.05 was considered significant. Table 1 presents background characteristics of patients with localized prostate cancer who subsequently underwent IMRT or 3DCRT. There were no significant differences in patient age, estimated prostate volume before hormonal therapy, and Gleason's score before hormonal therapy among the three protocols. Radiation dose was highest in the IMRT group and lowest in the old 3DCRT group. Serum prostate-specific antigen (PSA) level before hormonal therapy and clinical tumor stage were significantly higher in the IMRT group than in the new 3DCRT group. The 3 groups showed similar levels of comorbidities except for heart disease.
Results
Demographic characteristics
HRQL assessment
Comparison between general and disease-specific HRQL domains between the IMRT and 3DCRT groups is shown in Figures 1 and 2 . Total numbers of questionnaires assessed were 61 (32, 9 and 20), 84 (37, 19 and 28), and 112 (46, 28 and 38), just before initiation of radiotherapy, just after termination of radiotherapy, and 12 months after radiotherapy (for the IMRT, old and new 3DCRT groups), respectively.
HRQL assessed by SF-36 was almost similar in the three groups throughout the follow-up period. According to assessment of urinary function, no statistically significant differences were present among the study arms as well. However, the three treatment groups showed a similar marked urinary bother score throughout the follow-up period. Namely, the scores significantly worsened during radiation therapy, and returned 
Discussion
Normal tissue tolerance, especially of the rectum, is a limiting factor in definitive radiation treatment of prostate cancer. IMRT is a sophisticated method of delivering radiation and represents a promising new advance in the field of radiation oncology. 6, 7 Dose patterns delivered by this radiation method allow for dose escalation delivery to the tumor while sparing surrounding normal tissues. Thus, this treatment method is expected to lessen adverse effects to treatment-specific and general qualities of life, and to improve outcomes of cancer control.
This study demonstrated overall stability in general HRQL in 3DCRT and the IMRT groups, and no significant difference among the three groups was observed throughout the follow-up period, although the radiation doses prescribed differed from one another. This observation was compatible with many previous studies on conventional or conformal radiation therapy, in which general HRQL was assessed using SF-36. [13] [14] [15] [16] However, our previous study using the Japanese version of the European Organization for Research and Treatment of Cancer Prostate Cancer Quality-of-Life Questionnaire (EORTC-P) revealed a dynamic alteration of several domains in general HRQL including 'physical function,' 'physical symptoms,' 'fatigue/malaise,' and 'psychological distress' up to 1 year after conventional radiation therapy. 16 Discrepancies in results may be from differences in the instruments used for testing, suggesting that general HRQL assessment highly depends on the instruments used. The SF-36 may not be sufficiently sensitive to detect alterations or differences in general HRQL for evaluation of patients with localized prostate cancer.
Compared to general HRQL, several domains of disease-specific HRQL assessed using UCLA PCI showed marked alterations during the follow-up period, in our groups. These alterations clearly resulted from Quality-of-life after IMRT for prostate cancer K Yoshimura et al acute toxicity of radiation, and time-dependent recovery. Zelefsky et al. 7 reported acute and late toxicities in 772 patients treated with IMRT up to 86.4 Gy. In their series, acute grade 2 or more rectal toxicity, acute grade 2 or more urinary toxicity, late grade 2 or more rectal toxicity, and late grade 2 or more urinary toxicity occurred in 4, 28, 2 and 10% of patients, respectively. They insisted that IMRT markedly decreased acute and late rectal toxicities compared to 3DCRT, and that reduction of toxicity was an important impact on QOL. However, in our questionnaire-based study, significant differences were not observed in sequential alterations of the disease-specific QOL among the three treatment groups. This is reasonable because the IMRT protocol was designed so that the rectal wall receives a dose similar to that in the old 3DCRT. Additionally, it is suggested that higher dose irradiation beyond 70 Gy to part of the bladder wall is well tolerated.
In previous studies, rate of urinary leakage was reported to account for between 32 and 38%, and incontinence requiring the use of a pad was reported to affect between 3 and 15% of patients after XRT. 18, 19 Our study demonstrated various results according to treatment options; rates of urinary leakage and pad use were 50 and 17% in the old 3DCRT group, 18 and 4% in the new 3DCRT group, and 27 and 11% in the IMRT group, just after treatment (data not shown). Despite these differences, overall score of urinary function did not differ among the three groups throughout the follow-up period. On the other hand, urinary bother markedly deteriorated just after treatment, which recovered to baseline level 1 year after treatment. These observations were similar in all groups. We cannot clearly explain discrepancies between temporal trends of domains of urinary function and urinary bother. Some other factors affecting urinary incontinence, not including urinary function in the UCLA-PCI, may be responsible for the marked deterioration of urinary bother just after treatment.
Previous studies reported that bowel irritability and bleeding may occur following XRT for localized prostate cancer, but these symptoms tended to improve with time. [20] [21] [22] Our observations were compatible with these reports, and we showed that IMRT had a similar impact on bowel function and bothersomeness to 3DCRT. Regarding sexual function, Litwin et al. 23 reported that patients undergoing XRT for early-stage prostate cancer began to show declining sexual function during the second year after treatment. Beckendorf et al. 24 reported that 67% of male patients treated with XRT alone preserved sexual function 2 years post-treatment. Our previous study using a validated Japanese questionnaire on sexual function showed that early deterioration of sexual function after XRT was maintained up to 3 years after treatment. 17 On the other hand, the present study demonstrated sequential improvement in sexual function during the follow-up period. This observation may result from the use of neoadjuvant hormone therapy before radiation. A longer follow-up period is warranted for determination of genuine effects of 3DCRT and IMRT on sexual function. Despite significant improvement in sexual function, sexual bothersomeness showed no alteration during the follow-up period. Japanese attitude toward sexual activity may be responsible for this Quality-of-life after IMRT for prostate cancer K Yoshimura et al discrepancy between sexual function and bothersomeness. As Kakehi et al. 12 suggested, Japanese patients with decreased sexual activity feel less sexual dissatisfaction than did American patients do. Likely, Masumori et al. 25 reported that elderly Japanese men, unlike their American counterparts, did not report dissatisfaction with their sexual life, even if asked about erectile dysfunction.
While the overall results of the present study showed no apparent difference among the three treatment groups regarding HRQL despite different radiation doses, this study had several limitations. Firstly, our study included a relatively small number of patients. Secondly, we did not assess HRQL before the initiation of hormonal ablation, which should be accounted as another additional potential flaw in this study. Thirdly, treatment was not performed in a random fashion, but was selected by each patient and his urologist. This may have introduced a sampling bias if the three groups had apparent or unapparent baseline differences.
Despite these limitations, our observations have important implications for men faced with the choice of radiation for early-stage prostate cancer. Additional studies documenting long-term cancer control and HRQL evaluation are necessary to compare 3DCRT and IMRT since late adverse effects resulting from radiation therapy can occur during a long-term follow-up over a period of several years to decades.
Conclusion
The three approaches used in this study showed similar patterns of alterations regarding general and diseasespecific HRQL for the first year after radiation therapy.
Comparison of results between the 3DCRT and the IMRT groups revealed no substantial degrees of impairment in rectal toxicity and sexual function despite the dose escalation in the IMRT protocol. Thus, IMRT seems to offer a good treatment delivery approach with favorable HRQL outcomes.
